TY - JOUR
T1 - Ulcerative colitis
AU - Ungaro, Ryan
AU - Mehandru, Saurabh
AU - Allen, Patrick B.
AU - Peyrin-Biroulet, Laurent
AU - Colombel, Jean Frédéric
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/4/29
Y1 - 2017/4/29
N2 - Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of management is to induce and then maintain remission, defined as resolution of symptoms and endoscopic healing. Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs with new targets will rapidly increase in coming years.
AB - Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. Patients with ulcerative colitis have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. Ulcerative colitis usually presents with bloody diarrhoea and is diagnosed by colonoscopy and histological findings. The aim of management is to induce and then maintain remission, defined as resolution of symptoms and endoscopic healing. Treatments for ulcerative colitis include 5-aminosalicylic acid drugs, steroids, and immunosuppressants. Some patients can require colectomy for medically refractory disease or to treat colonic neoplasia. The therapeutic armamentarium for ulcerative colitis is expanding, and the number of drugs with new targets will rapidly increase in coming years.
UR - http://www.scopus.com/inward/record.url?scp=85007426226&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(16)32126-2
DO - 10.1016/S0140-6736(16)32126-2
M3 - Review article
C2 - 27914657
AN - SCOPUS:85007426226
SN - 0140-6736
VL - 389
SP - 1756
EP - 1770
JO - The Lancet
JF - The Lancet
IS - 10080
ER -